boule-shutterstock-com-cherry-
Boule / Shutterstock.com
24 March 2016Big PharmaJoachim Wachenfeld and Oswin Ridderbusch

A second bite at the cherry

Second medical use claims have a long-standing history in European Patent Office (EPO) case law. As is well known, the first ever decision of the EPO’s Enlarged Board of Appeal confirmed the patentability of second medical use claims when written in the so-called Swiss-type format. The Enlarged Board in that 1984 decision, G5/83, held that protection was available for “specified new and inventive therapeutic application[s]”. In the years that followed the technical boards of appeal controversially discussed what exactly was meant by the “specified therapeutic applications” referred to by the Enlarged Board.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
19 March 2026   The Swiss generics giant secures global commercialisation rights as partnership targets multi-billion-dollar loss-of-exclusivity opportunity.
Big Pharma
16 March 2026   Research from the International Trademark Association finds in-house counsel taking on more strategic work while facing shrinking budgets, prompting a shift towards alternative billing and greater use of AI.
Big Pharma
10 March 2026   UK government funding will support the London-based IP crime unit until 2029, as EUIPO and European authorities step up efforts to tackle unsafe counterfeits.